Gbs Inc. GBS
We take great care to ensure that the data presented and summarized in this overview for GBS Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GBS
View allLatest Institutional Activity in GBS
Top Purchases
Top Sells
About GBS
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Insider Transactions at GBS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 20
2024
|
Spiro Kevin Sakiris Chief Financial Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
9,394
+32.88%
|
-
|
|
Oct 04
2023
|
Christopher Towers Director |
BUY
Open market or private purchase
|
Direct |
9,090
+47.92%
|
-
|
|
Oct 04
2023
|
Spiro Kevin Sakiris Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
112,727
+48.98%
|
-
|
|
Sep 01
2023
|
Harry Simeonidis CEO |
BUY
Open market or private purchase
|
Direct |
50
+1.18%
|
$50
$1.85 P/Share
|
|
Aug 31
2023
|
Harry Simeonidis CEO |
BUY
Open market or private purchase
|
Direct |
100
+2.36%
|
$100
$1.92 P/Share
|
|
May 10
2023
|
Spiro Kevin Sakiris Chief Financial Officer |
BUY
Conversion of derivative security
|
Indirect |
2,399
+33.58%
|
$11,995
$5.8 P/Share
|
|
Oct 10
2022
|
Harry Simeonidis CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+49.81%
|
-
|
|
Oct 10
2022
|
Jonathan Scott Hurd Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Oct 10
2022
|
Christopher Towers Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+48.7%
|
-
|
|
Oct 10
2022
|
George Margelis Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Oct 10
2022
|
Spiro Kevin Sakiris Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+37.46%
|
-
|
|
Oct 10
2022
|
Lawrence B Fisher Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Oct 10
2022
|
Steven Constantine Boyages Interim CEO and Chairperson |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|
|
Jun 22
2022
|
Spiro Kevin Sakiris Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+9.05%
|
$0
$0.65 P/Share
|
|
Jun 17
2022
|
Spiro Kevin Sakiris Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,970
+26.1%
|
$0
$0.61 P/Share
|
|
Feb 17
2022
|
Life Science Biosensor Diagnostics Pty LTD |
SELL
Open market or private sale
|
Direct |
576,028
-34.75%
|
$0
$0.51 P/Share
|
|
Feb 16
2022
|
Life Science Biosensor Diagnostics Pty LTD |
SELL
Open market or private sale
|
Direct |
100,000
-5.69%
|
$0
$0.63 P/Share
|
|
Feb 15
2022
|
Life Science Biosensor Diagnostics Pty LTD |
SELL
Open market or private sale
|
Direct |
100,000
-5.38%
|
$0
$0.68 P/Share
|
|
Feb 14
2022
|
Life Science Biosensor Diagnostics Pty LTD |
SELL
Open market or private sale
|
Direct |
100,000
-5.11%
|
$0
$0.7 P/Share
|
|
Feb 11
2022
|
Life Science Biosensor Diagnostics Pty LTD |
SELL
Open market or private sale
|
Direct |
100,000
-4.86%
|
$0
$0.75 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 122K shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 9.39K shares |